insights_auto
Prečo akcie RARE stúpli 3,19%?
Preskúmať podrobnejšiechevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
15,22 USD
arrow_upward
+3,19%(+0,47) 1 d.
2. 10., 16:00:00 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre RARE…
Otvoriť
14,90 USD
Vysoká
15,28 USD
Nízka
14,67 USD
Trh. kap.
1,50 mld.
Priem. obj.
5,72 mil.
Objem
0,00
Max. za 52 týž.
39,89 USD
Min. za 52 týž.
12,73 USD
Výnosy na akciu
-5,84 USD
Beta
0,35
Akcie v obehu
98,59 mil.
Počet zamestnancov
1 tis.
Otvoriť
14,90 USD
Vysoká
15,28 USD
Nízka
14,67 USD
Trh. kap.
1,50 mld.
Priem. obj.
5,72 mil.
Objem
0,00
Max. za 52 týž.
39,89 USD
Min. za 52 týž.
12,73 USD
Výnosy na akciu
-5,84 USD
Beta
0,35
Akcie v obehu
98,59 mil.
Počet zamestnancov
1 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Yahoo Finance
·
pred 18 minútami
Stock Market: Will S&P 500 Open Up or Down Today?
Briefs Finance
·
pred 28 minútami
OKX and ICE Launch Tokenized NYSE Stocks
TradingView
·
pred 27 minútami
IXIC: Nasdaq Futures Flash Green as Traders Double Down on Risk. Rate-Hike Fear Is Fading
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Informácie o subjekte Ultragenyx Pharmaceutical Inc
Generálny riaditeľEmil Kakkis
Zamestnanci1,37 tis.
Dátum založenia2010
Hlavné sídloNovato, Kalifornia, Spojené štáty americké
Odvetvie-